Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.
Plos One|May 15, 2013
A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancerIssei Kurahashi, Yoshihiko Fujita, Tokuzo Arao, et al.
JAMA|April 18, 2023
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical TrialJun Watanabe, Kei Muro, Kohei Shitara, et al.
Nature Medicine|February 12, 2024
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerKohei Shitara, Kei Muro, Jun Watanabe, et al.
Therapeutic Advances in Medical Oncology|February 24, 2025
Comparison of inflammatory markers before and after nanoliposomal irinotecan and fluorouracil with folic acid in patients with pancreatic cancer: results from the NAPOLEON-2 study (NN-2302)Tomonori Araki, Kohei Hayashi, Mototsugu Shimokawa, et al.
Asia-Pacific Journal of Clinical Oncology|November 4, 2025
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 StudyAtsuko Kakihara, Shigeyuki Takeshita, Mototsugu Shimokawa, et al.
BMC Cancer|October 22, 2025
Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 studyKazuo Nishikawa, Taiga Otsuka, Mototsugu Shimokawa, et al.
Frontiers in Oncology|August 1, 2025
Efficacy of third-line chemotherapy following nanoliposomal irinotecan combined with fluorouracil and folinic acid as second-line treatment for unresectable pancreatic cancerKeisuke Miwa, Reina Kawasaki, Mototsugu Shimokawa, et al.
Scientific Reports|January 27, 2025
Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, et al.
Therapeutic Advances in Medical Oncology|November 21, 2025
Impact of prior chemotherapy on nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer: a retrospective analysis of data from the multicenter NAPOLEON-2 studyTomomi Koike, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.
Pageof 9